Insmed (INSM) Stock Forecast & Price Target

Compare

969 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

INSM Analyst Ratings

Strong Buy

16 Buy

2 Hold

0 Sell

Based on 18 analysts giving stock ratings to

Insmed

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

INSM Stock 12 Month Forecast

Average Price Target

$152.25

▲(4.93% Upside)

Based on 18 Wall Street analysts offering 12 month price targets for Insmed in the last 3 months. The average price target is $152.25 with a high forecast of $240.00 and a low forecast of $110.00. The average price target represents a 4.93% change from the last price of $145.10.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"67":"$67","154":"$154","241":"$241","110.5":"$110.5","197.5":"$197.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":240,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$240.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":152.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$152.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":110,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$110.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[67,110.5,154,197.5,241],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,145.3,152.5846153846154,159.86923076923077,167.15384615384616,174.43846153846155,181.72307692307692,189.0076923076923,196.2923076923077,203.5769230769231,210.86153846153846,218.14615384615385,225.43076923076922,232.7153846153846,{"y":240,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,145.3,145.8346153846154,146.36923076923077,146.90384615384616,147.43846153846155,147.97307692307692,148.5076923076923,149.0423076923077,149.5769230769231,150.11153846153846,150.64615384615385,151.18076923076924,151.7153846153846,{"y":152.25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,145.3,142.5846153846154,139.86923076923077,137.15384615384616,134.43846153846155,131.72307692307692,129.0076923076923,126.2923076923077,123.57692307692308,120.86153846153846,118.14615384615385,115.43076923076923,112.71538461538461,{"y":110,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":76.47,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":72.88,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.32,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":72.42,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":69.04,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":76.58,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":81.55,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":72,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":72.64,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":71.68,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":97.62,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":108.69,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 52,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":145.3,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$240.00

Average Price Target$152.25

Lowest Price Target$110.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Tiago Fauth

Wells Fargo

$140→$171

Buy

17.85%

Upside

Reiterated

09/03/25

Analysts' Top Healthcare Picks: Healthequity (HQY), Insmed (INSM)

Joseph Schwartz

Leerink Partners

$133→$150

Buy

3.38%

Upside

Reiterated

09/02/25

Insmed's Strategic Advancements and Market Potential: A Buy Recommendation

Jessica Fye

J.P. Morgan

―

Buy

―

Reiterated

09/02/25

Optimistic Buy Rating for Insmed: TPIP's Potential in the IPF Market

Jason Zemansky

Bank of America Securities

$142

Buy

-2.14%

Downside

Reiterated

09/02/25

Insmed's Growth Potential Highlighted by TPIP's Market Opportunity and Positive Outlook

Stephen Willey

Stifel Nicolaus

$121→$145

Buy

-0.07%

Downside

Reiterated

09/02/25

Optimistic Buy Rating for Insmed's TPIP Driven by Promising TETON-2 Trial Results and Market Potential in IPF Treatment

Maxwell Skor

Morgan Stanley

$144

Hold

-0.76%

Downside

Reiterated

09/02/25

Cautious Hold Rating on Insmed Amid Positive IPF Trial Results and Awaited Strategic Clarity

Graig Suvannavejh

Mizuho Securities

$165

Buy

13.71%

Upside

Reiterated

09/02/25

Mizuho Securities Keeps Their Buy Rating on Insmed (INSM)with our current $165 PT implying 21% upside from last Friday's close (and IPF not yet modeled), we reiterate our OP rating on INSM.

Matt Phipps

William Blair

―

Buy

―

Reiterated

09/02/25

Buy Rating for Insmed: Promising Market Potential and Strategic Advancements in TPIP Development

Gavin Clark-Gartner

Evercore ISI

$90→$110

Buy

-24.19%

Downside

Initiated

08/22/25

Evercore ISI Sticks to Their Buy Rating for Insmed (INSM)

Owen Dosehart

TR | OpenAI - 4o

$121→$135

Hold

-6.96%

Downside

Reiterated

08/20/25

AI Generated ArticleAI Generated Article

Andy Chen

Wolfe Research

$109→$173

Buy

19.23%

Upside

Reiterated

08/14/25

Wolfe Research Sticks to Their Buy Rating for Insmed (INSM)Wolfe Research analyst Andy Chen raised the price target on Insmed (NASDAQ: INSM) to $173.00 (from $109.00) while maintaining a Outperform rating.

Srikripa Devarakonda

Truist Financial

$126→$139

Buy

-4.20%

Downside

Reiterated

08/14/25

Truist Financial Sticks to Its Buy Rating for Insmed (INSM)

Ritu Baral

TD Cowen

$135→$154

Buy

6.13%

Upside

Reiterated

08/13/25

Insmed's Brensocatib Approval Boosts Market Potential and Stock Valuation

Andrew Fein

H.C. Wainwright

$120→$240

Buy

65.40%

Upside

Reiterated

08/13/25

H.C. Wainwright Remains a Buy on Insmed (INSM)

Trung Huynh

UBS

$133→$140

Buy

-3.51%

Downside

Reiterated

08/13/25

Insmed (INSM) Receives a Buy from UBS

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Tiago Fauth

Wells Fargo

$140→$171

Buy

17.85%

Upside

Reiterated

09/03/25

Analysts' Top Healthcare Picks: Healthequity (HQY), Insmed (INSM)

Joseph Schwartz

Leerink Partners

$133→$150

Buy

3.38%

Upside

Reiterated

09/02/25

Insmed's Strategic Advancements and Market Potential: A Buy Recommendation

Jessica Fye

J.P. Morgan

―

Buy

―

Reiterated

09/02/25

Optimistic Buy Rating for Insmed: TPIP's Potential in the IPF Market

Jason Zemansky

Bank of America Securities

$142

Buy

-2.14%

Downside

Reiterated

09/02/25

Insmed's Growth Potential Highlighted by TPIP's Market Opportunity and Positive Outlook

Stephen Willey

Stifel Nicolaus

$121→$145

Buy

-0.07%

Downside

Reiterated

09/02/25

Optimistic Buy Rating for Insmed's TPIP Driven by Promising TETON-2 Trial Results and Market Potential in IPF Treatment

Maxwell Skor

Morgan Stanley

$144

Hold

-0.76%

Downside

Reiterated

09/02/25

Cautious Hold Rating on Insmed Amid Positive IPF Trial Results and Awaited Strategic Clarity

Graig Suvannavejh

Mizuho Securities

$165

Buy

13.71%

Upside

Reiterated

09/02/25

Mizuho Securities Keeps Their Buy Rating on Insmed (INSM)with our current $165 PT implying 21% upside from last Friday's close (and IPF not yet modeled), we reiterate our OP rating on INSM.

Matt Phipps

William Blair

―

Buy

―

Reiterated

09/02/25

Buy Rating for Insmed: Promising Market Potential and Strategic Advancements in TPIP Development

Gavin Clark-Gartner

Evercore ISI

$90→$110

Buy

-24.19%

Downside

Initiated

08/22/25

Evercore ISI Sticks to Their Buy Rating for Insmed (INSM)

Owen Dosehart

TR | OpenAI - 4o

$121→$135

Hold

-6.96%

Downside

Reiterated

08/20/25

AI Generated ArticleAI Generated Article

Andy Chen

Wolfe Research

$109→$173

Buy

19.23%

Upside

Reiterated

08/14/25

Srikripa Devarakonda

Truist Financial

$126→$139

Buy

-4.20%

Downside

Reiterated

08/14/25

Truist Financial Sticks to Its Buy Rating for Insmed (INSM)

Ritu Baral

TD Cowen

$135→$154

Buy

6.13%

Upside

Reiterated

08/13/25

Insmed's Brensocatib Approval Boosts Market Potential and Stock Valuation

Andrew Fein

H.C. Wainwright

$120→$240

Buy

65.40%

Upside

Reiterated

08/13/25

H.C. Wainwright Remains a Buy on Insmed (INSM)

Trung Huynh

UBS

$133→$140

Buy

-3.51%

Downside

Reiterated

08/13/25

Insmed (INSM) Receives a Buy from UBS

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Insmed

1 Month

xxx

Success Rate

14/22 ratings generated profit

Average Return

+14.19%

reiterated a xxx

rating 25 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 63.64% of your transactions generating a profit, with an average return of +14.19% per trade.

3 Months

xxx

Success Rate

19/23 ratings generated profit

Average Return

+36.92%

reiterated a xxx

rating 5 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 82.61% of your transactions generating a profit, with an average return of +36.92% per trade.

1 Year

Andrew FeinH.C. Wainwright

Success Rate

15/15 ratings generated profit

Average Return

+111.39%

reiterated a buy rating 25 days ago

Copying Andrew Fein's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +111.39% per trade.

2 Years

xxx

Success Rate

14/14 ratings generated profit

Average Return

+232.57%

reiterated a xxx

rating 4 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +232.57% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

INSM Analyst Recommendation Trends

Rating

May 25

Jun 25

Jul 25

Aug 25

Sep 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, INSM has received 43 Buy Ratings, 8 Hold Ratings, and 0 Sell Ratings. INSM average Analyst price target in the past 3 months is 152.25.

Each month's total comprises the sum of three months' worth of ratings.

INSM Financial Forecast

INSM Earnings Forecast

Next quarter’s earnings estimate for INSM is -$1.33 with a range of -$1.67 to -$1.11. The previous quarter’s EPS was -$1.70. INSM beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.17% of the time in the same period. In the last calendar year INSM has Preformed in-line its overall industry.

INSM Sales Forecast

Next quarter’s sales forecast for INSM is $114.72M with a range of $106.00M to $121.97M. The previous quarter’s sales results were $107.42M. INSM beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.33% of the time in the same period. In the last calendar year INSM has Outperformed its overall industry.

INSM Stock Forecast FAQ

What is INSM’s average 12-month price target, according to analysts?

Based on analyst ratings, Insmed’s 12-month average price target is 152.25.

What is INSM’s upside potential, based on the analysts’ average price target?

Insmed has 4.93% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is INSM a Buy, Sell or Hold?

Insmed has a consensus rating of Strong Buy which is based on 16 buy ratings, 2 hold ratings and 0 sell ratings.

What is Insmed’s price target?

The average price target for Insmed is 152.25. This is based on 18 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $240.00 ,the lowest forecast is $110.00. The average price target represents 4.93% Increase from the current price of $145.1.

What do analysts say about Insmed?

Insmed’s analyst rating consensus is a Strong Buy. This is based on the ratings of 18 Wall Streets Analysts.

How can I buy shares of INSM?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Insmed (INSM) Stock Forecast & Price Target

INSM Analyst Ratings

INSM Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Insmed

INSM Analyst Recommendation Trends

INSM Financial Forecast

INSM Earnings Forecast

INSM Sales Forecast

INSM Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts